VEXAS anemia is a mosaic erythroblastopenia

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• VEXAS syndrome is an autoinflammatory disorder caused by somatic UBA1 mutations.
• It leads to cytoplasm-restricted ubiquitylation defects and poorly understood macrocytic anemia.

Purpose of the Study:

• Investigate the erythroid lineage's role in VEXAS-associated anemia.
• Clarify the impact of UBA1 mutations on red blood cell development.

Main Methods:

• In vivo analysis of patient red cells and erythroblasts.
• In vitro base-editing models of erythropoiesis using CD34+ cells.
• Assessment of ubiquitylation, TP53 expression, and ribosome biogenesis.

Main Results:

• Mature red cells show no ubiquitylation defects.
• UBA1 mutations impact erythroblasts before the basophilic stage.
• UBA1 variant editing caused high mortality in early erythroid differentiation, linked to TP53 overexpression and ribosome anomalies.

Conclusions:

• VEXAS anemia may stem from mosaic erythroblastopenia affecting early erythroid development.
• Severity correlates with the functional UBA1 compartment.
• Findings offer insights into VEXAS pathophysiology and potential therapies.